Implications for IV posaconazole dosing in the era of obesity

  • Wasmann, Roeland E
  • Smit, Cornelis
  • van Donselaar, Marieke H
  • van Dongen, Eric P A
  • Wiezer, René M J
  • Verweij, Paul E
  • Burger, David M
  • Knibbe, Catherijne A J
  • Brüggemann, Roger J M

  • Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

    Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands

    Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands

    Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

    Department of Anaesthesiology, Intensive Care and Pain Management, St Antonius Hospital, Nieuwegein, The Netherlands

    Department of Surgery, St Antonius Hospital, Nieuwegein, The Netherlands

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

Corresponding author. E-mail: [email protected]

Received September 27, 2019

Received in revised form December 04, 2019

Accepted December 6, 2019

Journal of Antimicrobial Chemotherapy 75(4):p 1006-1013, April 2020. | DOI: 10.1093/jac/dkz546
Copyright © British Society for Antimicrobial Chemotherapy 2020. Published by Oxford University Press. All rights reserved.
View full text|Download PDF